Showing 1 - 7 results of 7 for search 'Laura Mansi', query time: 0.03s Refine Results
  1. 1
    Cardiotoxicity is mitigated after a supervised exercise program in HER2-positive breast cancer undergoing adjuvant trastuzumab

    Cardiotoxicity is mitigated after a supervised exercise program in HER2-positive breast cancer undergoing adjuvant trastuzumab by Quentin Jacquinot, Quentin Jacquinot, Nathalie Meneveau, Antoine Falcoz, Malika Bouhaddi, Malika Bouhaddi, Pauline Roux, Bruno Degano, Marion Chatot, Elsa Curtit, Elsa Curtit, Laura Mansi, Laura Mansi, Marie-Justine Paillard, Fernando Bazan, Loïc Chaigneau, Erion Dobi, Guillaume Meynard, Dewi Vernerey, Xavier Pivot, Fabienne Mougin, Fabienne Mougin

    Published 2022-09-01
    Get full text
    Article
  2. 2
    Efficacy of trabectedin in metastatic solitary fibrous tumor

    Efficacy of trabectedin in metastatic solitary fibrous tumor by Xavier Pivot, Laura Mansi, Stephanie Servagi-Vernat, Delphine Delroeux, Julien Pauchot, Lionel Aherfi, Nicolas Isambert, Christine Fagnoni-Legat, Elsa Kalbacher, Antoine Thiery-Vuillemin, Loic Chaigneau

    Published 2011-07-01
    Get full text
    Article
  3. 3
    A randomized trial to evaluate the effects of a supervised exercise program on insomnia in patients with non-metastatic breast cancer undergoing chemotherapy: design of the FATSOMCAN study

    A randomized trial to evaluate the effects of a supervised exercise program on insomnia in patients with non-metastatic breast cancer undergoing chemotherapy: design of the FATSOMC... by Chloé Drozd, Elsa Curtit, Quentin Jacquinot, Charlène Marquine, Laura Mansi, Loïc Chaigneau, Erion Dobi, Julien Viot, Guillaume Meynard, Marie-Justine Paillard, Morgan Goujon, Pauline Roux, Dewi Vernerey, Valérie Gillet, Hubert Bourdin, Silvio Galli, Nathalie Meneveau, Fabienne Mougin

    Published 2023-05-01
    Get full text
    Article
  4. 4
    <i>ATG9A</i> Is Overexpressed in Triple Negative Breast Cancer and Its In Vitro Extinction Leads to the Inhibition of Pro-Cancer Phenotypes

    <i>ATG9A</i> Is Overexpressed in Triple Negative Breast Cancer and Its In Vitro Extinction Leads to the Inhibition of Pro-Cancer Phenotypes by Aurore Claude-Taupin, Leïla Fonderflick, Thierry Gauthier, Laura Mansi, Jean-René Pallandre, Christophe Borg, Valérie Perez, Franck Monnien, Marie-Paule Algros, Marc Vigneron, Pascale Adami, Régis Delage-Mourroux, Paul Peixoto, Michael Herfs, Michaël Boyer-Guittaut, Eric Hervouet

    Published 2018-12-01
    Get full text
    Article
  5. 5
    A Phase II Study Evaluating the Interest to Combine UCPVax, a Telomerase CD4 TH1-Inducer Cancer Vaccine, and Atezolizumab for the Treatment of HPV Positive Cancers: VolATIL Study

    A Phase II Study Evaluating the Interest to Combine UCPVax, a Telomerase CD4 TH1-Inducer Cancer Vaccine, and Atezolizumab for the Treatment of HPV Positive Cancers: VolATIL Study by Magali Rebucci-Peixoto, Magali Rebucci-Peixoto, Angélique Vienot, Angélique Vienot, Angélique Vienot, Olivier Adotevi, Olivier Adotevi, Olivier Adotevi, Marion Jacquin, Marion Jacquin, Francois Ghiringhelli, Christelle de la Fouchardière, Benoit You, Tristan Maurina, Elsa Kalbacher, Fernando Bazan, Guillaume Meynard, Anne-Laure Clairet, Christine Fagnoni-Legat, Laurie Spehner, Adeline Bouard, Dewi Vernerey, Dewi Vernerey, Aurélia Meurisse, Aurélia Meurisse, Stefano Kim, Stefano Kim, Stefano Kim, Christophe Borg, Christophe Borg, Christophe Borg, Laura Mansi

    Published 2022-07-01
    Get full text
    Article
  6. 6
    Author Correction: Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial

    Author Correction: Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast ca... by Laurence Buisseret, Delphine Loirat, Philippe Aftimos, Christian Maurer, Kevin Punie, Véronique Debien, Paulus Kristanto, Daniel Eiger, Anthony Goncalves, François Ghiringhelli, Donatienne Taylor, Florent Clatot, Tom Van den Mooter, Jean-Marc Ferrero, Hervé Bonnefoi, Jean-Luc Canon, Francois P. Duhoux, Laura Mansi, Renaud Poncin, Philippe Barthélémy, Nicolas Isambert, Zoë Denis, Xavier Catteau, Roberto Salgado, Elisa Agostinetto, Evandro de Azambuja, Françoise Rothé, Ligia Craciun, David Venet, Emanuela Romano, John Stagg, Marianne Paesmans, Denis Larsimont, Christos Sotiriou, Michail Ignatiadis, Martine Piccart-Gebhart

    Published 2023-12-01
    Get full text
    Article
  7. 7
    Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial

    Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomize... by Laurence Buisseret, Delphine Loirat, Philippe Aftimos, Christian Maurer, Kevin Punie, Véronique Debien, Paulus Kristanto, Daniel Eiger, Anthony Goncalves, François Ghiringhelli, Donatienne Taylor, Florent Clatot, Tom Van den Mooter, Jean-Marc Ferrero, Hervé Bonnefoi, Jean-Luc Canon, Francois P. Duhoux, Laura Mansi, Renaud Poncin, Philippe Barthélémy, Nicolas Isambert, Zoë Denis, Xavier Catteau, Roberto Salgado, Elisa Agostinetto, Evandro de Azambuja, Françoise Rothé, Ligia Craciun, David Venet, Emanuela Romano, John Stagg, Marianne Paesmans, Denis Larsimont, Christos Sotiriou, Michail Ignatiadis, Martine Piccart-Gebhart

    Published 2023-11-01
    Get full text
    Article

Search Tools: